Keros Therapeutics, Inc. - 8-K Filing
Keros Therapeutics updates corporate presentation detailing rinvatercept (KER-065) clinical development and pipeline strategy. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $KROS